AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comSEP 262 min read$TECH

Bio-Techne (TECH) Shareholders Approve the Merck KGaA Takeover and Reject the Pay Package

Bio-Techne (TECH) shareholders approved a $11.3B takeover by Merck KGaA at $73/share, but rejected the executive pay package. Shares closed at $72.57. The deal, subject to remaining approvals, is expected to close in late 2026 or early 2027.

Original reporting
finance.yahoo.com
Published Sep 26, 2026, 3:57 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 26, 2026, 4:27 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Bio-Techne (TECH) Shareholders Approve the Merck KGaA Takeover and Reject the Pay Package — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$TECHBullishMed
01

Why it matters

The deal is expected to create a vertically integrated supplier with recurring revenue streams, enhancing earnings visibility for Merck KGaA.

02

Market read

The acquisition reshapes the global reagents market and may influence valuations of comparable biotech supply firms.

03

What to watch

The rejected executive pay package may signal governance friction that could affect post‑close integration.

Relevance 9/10Novelty 9/10Timing: post‑shareholder vote Sep 23

Background

Bio‑Techne provides laboratory reagents and antibodies; Merck KGaA has been building a life‑sciences portfolio.

Company-level read

Ticker impact

$TECHBullishHigh confidence
Context

Shareholders approved Merck KGaA's $73‑per‑share cash acquisition of Bio‑Techne, valuing it at about $11.3 billion.

Expected impact

TECH may trade near the $73 offer price, with upside if the market discounts the remaining regulatory risk.

Evidence & confidence

Deal size and cash premium are substantial; shareholder approval signals strong support, reducing uncertainty.

Market effects

Sector

Consolidates the life‑sciences reagents market, potentially pressuring peers such as Thermo Fisher and Agilent.

Regional

Strengthens Merck KGaA's presence in the U.S. biotech supply chain.

Global

One of the larger cross‑border M&A deals in the life‑sciences sector this year.

Counterpoint

What could challenge this read

Regulatory approvals outside the U.S. could stall, creating downside risk if antitrust concerns arise in Europe.

Key entities

  • company
    Bio‑Techne Corporation

    U.S. life‑sciences reagent supplier (NASDAQ:TECH).

  • company
    Merck KGaA

    German life‑sciences and chemicals group.

Read at source← All news

Related articles

SEP 26
$MRKHighAI 9/10

What Does Merck (MRK) FDA Approval In Advanced Kidney Cancer Mean?

Merck (MRK) and Eisai received FDA approval for Welireg plus Lenvima to treat advanced kidney cancer after prior immunotherapy. The approval is based on Phase 3 trial data. Merck, valued at $367.1b, aims to expand its oncology portfolio with this new regimen, positioning it against competitors like cabozantinib. Investors will watch how quickly the new treatment gains market share.

simplywall.st2 min
SEP 25
$MRKMedAI 8/10

Merck withdrew its lung cancer drug application. A phase 3 trial is still enrolling.

Merck and Daiichi Sankyo withdrew the Biologics License Application for ifinatamab deruxtecan in treating extensive-stage small cell lung cancer. The decision follows discussions with the FDA, but enrollment continues in a phase 3 trial. The drug is a B7-H3 directed antibody drug conjugate being jointly developed by the companies. Both firms expressed disappointment but remain committed to evaluating the drug's potential in other cancer types.

stocktitan.net2 min
SEP 25
$MRKMedAI 8/10

Merck (MRK) Withdraws I-DXd Biologics License Application for ES

Merck (MRK) withdrew its BLA for I-DXd in treating extensive-stage small cell lung cancer, citing insufficient data for accelerated approval. The company remains committed to ongoing clinical trials. MRK's dividend yield is 2.31% with a high payout ratio of 1.11, and its stock is 23.2% overvalued relative to its GF Value. The company has a GF Score of 83, reflecting strong profitability and growth but valuation concerns.

gurufocus.com2 min
SEP 25
$MRKLow

Merck, Daiichi withdraw ifinatamab FDA application

Merck (MRK) and Daiichi Sankyo (4568) withdrew a U.S. FDA application for their small cell lung cancer drug ifinatamab deruxtecan, citing insufficient data. The Phase 2 trial showed a 54.8% response rate at a higher dose. The companies continue a Phase 3 trial, nearing full enrollment, with no new filing timeline provided.

mugglehead.com2 min
SEP 25
$MRKHighAI 9/10

Merck, Daiichi Sankyo withdraw US application for lung cancer therapy

Merck and Daiichi Sankyo withdrew their US application for accelerated approval of their experimental lung cancer therapy, ifinatamab deruxtecan, after the FDA deemed the mid-stage clinical study data insufficient. The therapy was intended for treating extensive-stage small cell lung cancer in adults who had progressed after standard chemotherapy, according to the companies.

ksl.com2 min